Compare Quest Diagnostics Inc (DGX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Marathon Petroleum Corp — how do they compare? Quest Diagnostics Inc trades at $236.62 (market cap $26.21B), while Marathon Petroleum Corp trades at $337.5 (market cap $94.48B). The key difference: Marathon Petroleum Corp is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | MPC | |
|---|---|---|
Market Cap | $26.21B | $94.48B |
Sector | Health | Energy |
52-Week High | $238.50 | $336.42 |
52-Week Low | $173.49 | $159.11 |
Enterprise Value | $31.97B | $121.00B |
Dividend Yield | 1.45% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Marathon Petroleum (MPC) trades at $320.32, up 7.42% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations by 22.1%. The stock is in a bullish technical trend, supported by robust refining margins and disciplined operations. Recent news highlights MPC's advantage from global refining tightness and geopolitical disruptions. Valuation ratios like P/E of 11.67 and P/S of 0.65 suggest potential undervaluation relative to earnings growth.
Outlook remains positive with analyst consensus at Buy (75.76%) and a $332.70 price target, though risks include volatile energy markets and debt levels. Earnings growth and cash returns via dividends and buybacks are key catalysts, but investors should monitor refining margin sustainability and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
